Related Experiment Video
Updated: Jul 7, 2026
12:03
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
Angiotensin II receptor antagonists.
1Department of Medicine, Centre Hospitalier Universitaire, Lausanne, Switzerland. Michel.Burnier@chuv.hospvd.ch
Lancet (London, England)
|March 4, 2000
Summary
New angiotensin II receptor antagonists offer a more specific blockade of the renin-angiotensin system than older angiotensin-converting enzyme (ACE) inhibitors. These drugs show comparable efficacy in hypertensive patients and may offer future benefits in preventing cardiovascular disease.
Area of Science:
- Pharmacology and Cardiovascular Medicine
- Drug Development and Therapeutics
Background:
- The renin-angiotensin system (RAS) is a key regulator of cardiovascular function.
- Early research utilized pharmacological probes to study RAS, leading to the development of angiotensin-converting enzyme (ACE) inhibitors.
- ACE inhibitors, while effective, target a non-specific enzyme in the RAS cascade.
Purpose of the Study:
- To introduce and evaluate the significance of orally active angiotensin II receptor antagonists.
- To compare the efficacy of angiotensin II receptor antagonists with existing ACE inhibitors.
- To explore the potential of angiotensin II receptor antagonists in preventing target-organ damage and reducing cardiovascular events.
Main Methods:
- Review of pharmacological probes and their evolution into therapeutic agents.
- Analysis of the development and market availability of orally active angiotensin II receptor antagonists.
- Comparison of clinical efficacy data between angiotensin II receptor antagonists and ACE inhibitors, particularly in hypertensive patients.
Main Results:
- Angiotensin II receptor antagonists provide a more specific blockade of the RAS compared to ACE inhibitors.
- Current data indicate that angiotensin II receptor antagonists are equally effective as ACE inhibitors in managing hypertension.
- Several angiotensin II receptor antagonists are commercially available, with more under development.
Conclusions:
- Angiotensin II receptor antagonists represent a significant advancement in RAS blockade, offering greater specificity.
- These agents are a viable therapeutic option, demonstrating comparable efficacy to ACE inhibitors in hypertensive patients.
- Ongoing trials are crucial to determine if angiotensin II receptor antagonists can surpass ACE inhibitors in preventing long-term cardiovascular complications.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:27Angina II: Classification
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...